645378-53-6

Basic information

• Product Name: 1,1-dimethylethyl-4-[3-[{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}(methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-1-piperidinecarboxylate
• Synonyms: 1,1-dimethylethyl-4-[3-[{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}(methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-1-piperidinecarboxylate
• CAS NO: 645378-53-6
• Molecular Weight: 604.608
• Mol File: 645378-53-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1,1-dimethylethyl-4-[3-[{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}(methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-1-piperidinecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 1,1-dimethylethyl-4-[3-[{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}(methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-1-piperidinecarboxylate(645378-53-6)
• EPA Substance Registry System: 1,1-dimethylethyl-4-[3-[{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}(methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-1-piperidinecarboxylate(645378-53-6)

Safety Data

• Hazardous Substances Data: 645378-53-6(Hazardous Substances Data)

Upstream product

• 645378-25-2 4-[2-carboxy-1-(4-fluoro-phenyl)-ethyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 334477-60-0 [(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl](methyl)amine 

Relevant articles and documents

N-BENZYL-3-PHENYL-3-HETEROCYCLYL-PROPIONAMIDE COMPOUNDS AS TACHYKININ AND/ OR SEROTONIN REUPTAKE INHIBITORS

The present invention relates to heterocyclic derivatives of formula (1) wherein R1 represents a 5 or 6 membered heteroaryl group, in which the 5-membered heteroaryl group contains at least one heteroatom selected from oxygen, sulphur or nitrogen and the 6-membered heteroaryl group contains from 1 to 3 nitrogen atoms, or R1 represents a 4,5 or 6 membered heterocyclic group, wherein saids 5 or 6 membered heteroaryl or the 4,5 or 6 membered heterocyclic group may optionally be substituted by one to three substituents, which may be the same or different, selected from (CH2)pR6, wherein p is zero or an integer from 1 to 4 and wherein R and R2- R6 are each as defined in the description and pharmaceutically acceptable salts and solvates thereof; process for their preparation and their use in the treatment of conditions mediated by tachykinins and/or by selective inhibition of serotonin reuptake transporter protein.